CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 337 enrolled
Drug / intervention
TVT +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00460434
NCT00460434Phase 2Completed

Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling (OPUS) Trial

NICHD Pelvic Floor Disorders Network·interventional·Posted Apr 16, 2007·Updated May 30, 2018

In Brief

A Phase 2 clinical trial evaluating TVT and Sham for Pelvic Organ Prolapse. Completed, enrolled 337 participants across 8 sites.

Detailed Summary

Pelvic organ prolapse is common among women with a prevalence that has been estimated to be as high as 30%. Prolapse may be corrected by surgery using either a vaginal or abdominal incision. Some women develop stress urinary incontinence (SUI) after surgery. A prior randomized trial has shown that use of a Burch sling at the time of an abdominal sacrocolpopexy decreases the risk of urinary incontinence; however, the benefit of adding an anti incontinence procedure to prevent SUI at the time of prolapse surgery performed via a vaginal approach is unclear. Thus, the objective of the Outcomes following vaginal Prolapse repair and mid Urethral Sling (OPUS) trial is to determine whether prophylactic treatment with Tension-free Vaginal Tape (TVT)® at the time of prolapse surgery done via a vaginal approach is effective in preventing urinary incontinence.

Study Details

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 16, 2007
Enrollment StartMay 1, 2007
Primary CompletionJan 1, 2011
Study CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 19.2 years ago

Interventions

TVTdevice

Prophylactic TVT

Shamother

Sham TVT